Hepion Pharmaceuticals Inc (NASDAQ: HEPA) shares gained 3.52%, or $0.05 per share, to close Wednesday at $1.47. After opening the day at $1.45, shares of Hepion fluctuated between $1.48 and $1.41. 566,964 shares traded hands a decrease from their 30 day average of 965,244. Wednesday’s activity brought Hepion’s market cap to $112,051,110.
Hepion is headquartered in Edison, New Jersey..
About Hepion Pharmaceuticals Inc
The Company’s lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in preclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence – Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company’s footprint in the cyclophilin inhibition therapeutic space.